Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00235989 · ClinicalTrials.gov registry record · Phase 2

Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis

A Phase 2 study of Multiple Sclerosis (Relapsing Remitting), sponsored by Bayer.

Completed
Registry status
Phase 2
Development phase
63
Enrollment target
17
Study locations

NCT00235989 is a Phase 2 study of Multiple Sclerosis (Relapsing Remitting) that has completed, run by Bayer. The registered enrollment target is 63 participants, below the 560-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (89% lower). The trial reports 17 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00235989, a Phase 2 study of Multiple Sclerosis (Relapsing Remitting), has completed, sponsored by Bayer.

COMPLETED
Registry status
Phase 2
Development phase
63 participants
Enrollment target
17
Study locations

Study Summary

The purpose of this study is to determine if a higher dose of study drug is more effective in preventing relapses in patients with Multiple Sclerosis.

Conditions Studied

Multiple Sclerosis (Relapsing Remitting)

Interventions

  • DRUG Interferon beta 1b (Betaseron, BAY86-5046)

Study Locations (17)

North Carolina

  • - Durham
  • - High Point
  • - Winston-Salem

California

  • - Los Angeles
  • - San Francisco

Michigan

  • - Ann Arbor
  • - Ann Arbor

Tennessee

  • - Nashville
  • - Nashville

District of Columbia

  • - Washington D.C.

Georgia

  • - Atlanta

Illinois

  • - Chicago

Kansas

  • - Kansas City

Trial Details

FieldValue
Enrollment Target 63 participants
Start Date 2003-06
Est. Completion 2008-01
Phase Phase 2

Sponsor

Bayer

591 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00235989

The ClinicalTrials.gov registry entry for NCT00235989 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 560-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (89% lower). The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Sclerosis (Relapsing Remitting) appearing as the primary indexed condition, and to 1 intervention - of which Interferon beta 1b (Betaseron, BAY86-5046) is the first listed.

NCT00235989 reports 17 study locations spanning 12 distinct geographic areas - top geographies include North Carolina, California, Michigan.

Frequently Asked Questions

What is clinical trial NCT00235989 about?

NCT00235989 is a clinical study titled "Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis". The purpose of this study is to determine if a higher dose of study drug is more effective in preventing relapses in patients with Multiple Sclerosis.

What is the current status of trial NCT00235989?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2003-06. Estimated completion is 2008-01.

What conditions does trial NCT00235989 study?

This clinical trial studies the following conditions: Multiple Sclerosis (Relapsing Remitting).

What interventions are being tested in trial NCT00235989?

The interventions under investigation include: Interferon beta 1b (Betaseron, BAY86-5046) (DRUG).

Who is sponsoring clinical trial NCT00235989?

This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00235989 being conducted?

This trial has 17 study locations across California, District of Columbia, Georgia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Sclerosis (Relapsing Remitting)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Sclerosis (Relapsing Remitting)

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.